Larimar Therapeutics's three largest insider shareholders as of September 29, 2026 are James E Flynn (Director, 35.61Mn shares), Thomas Edward Hamilton (Director, 714.80K shares), Carole Ben-Maimon (President And Ceo, 368.28K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | James E Flynn | Director, TenPercentOwner, Other | 0 | 35,606,974 | 35,606,974 | 96.1% | 02 Mar, 2026 |
| 2 | Thomas Edward Hamilton | Director | 714,798 | 0 | 714,798 | 1.9% | 08 Jul, 2026 |
| 3 | Carole Ben-Maimon | President And Ceo | 368,276 | 0 | 368,276 | 1.0% | 27 Jan, 2026 |
| 4 | Michael Celano | Chief Financial Officer | 215,785 | 0 | 215,785 | 0.6% | 27 Jan, 2026 |
| 5 | Gopi Shankar | Chief Development Officer | 76,443 | 0 | 76,443 | 0.2% | 27 Jan, 2026 |
| 6 | Russell Clayton | Chief Medical Officer | 71,443 | 0 | 71,443 | 0.2% | 27 Jan, 2026 |
| 7 | Frank E Thomas | Director | 7,000 | 0 | 7,000 | 0.0% | 02 Mar, 2026 |
| 8 | Jeffrey W Sherman | Director | 5,000 | 0 | 5,000 | 0.0% | 02 Mar, 2026 |
| 9 | Joseph Truitt | Director | 2,750 | 0 | 2,750 | 0.0% | 18 May, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 06 Jul, 2026 | Thomas Edward Hamilton | Director | Acquired P | 50,000 | $3.34 | $166.89K | 714,798 | Direct |
| 19 May, 2026 | Frank E Thomas | Director | Acquired A | 55,150 | $0.00 | $0 | 55,150 | Direct |
| 19 May, 2026 | Jonathan S Leff | Director | Acquired A | 55,150 | $0.00 | $0 | 55,150 | Direct |
| 19 May, 2026 | Jeffrey W Sherman | Director | Acquired A | 55,150 | $0.00 | $0 | 55,150 | Direct |
| 19 May, 2026 | Joseph Truitt | Director | Acquired A | 55,150 | $0.00 | $0 | 55,150 | Direct |
| 19 May, 2026 | James E Flynn | Director, TenPercentOwner, Other | Acquired A | 55,150 | $0.00 | $0 | 55,150 | Indirect |
| 19 May, 2026 | Thomas Edward Hamilton | Director | Acquired A | 55,150 | $0.00 | $0 | 55,150 | Direct |
| 27 Feb, 2026 | Jeffrey W Sherman | Director | Acquired P | 5,000 | $5.00 | $25.00K | 5,000 | Direct |
| 27 Feb, 2026 | Frank E Thomas | Director | Acquired P | 5,000 | $5.00 | $25.00K | 7,000 | Direct |
| 27 Feb, 2026 | Thomas Edward Hamilton | Director | Acquired P | 100,000 | $5.00 | $500.00K | 664,798 | Direct |
| 27 Feb, 2026 | James E Flynn | Director, TenPercentOwner, Other | Acquired P | 1,084,010 | $5.00 | $5.42Mn | 10,622,928 | Indirect |
| 27 Feb, 2026 | James E Flynn | Director, TenPercentOwner, Other | Acquired P | 1,084,012 | $5.00 | $5.42Mn | 10,622,957 | Indirect |
| 27 Feb, 2026 | James E Flynn | Director, TenPercentOwner, Other | Acquired P | 831,978 | $5.00 | $4.16Mn | 8,153,107 | Indirect |
| 27 Feb, 2026 | James E Flynn | Director, TenPercentOwner, Other | Acquired P | 2,000,000 | $5.00 | $10.00Mn | 6,207,982 | Indirect |
| 26 Jan, 2026 | Carole Ben-Maimon | President And Ceo | Acquired A | 100,100 | $0.00 | $0 | 368,276 | Direct |
| 26 Jan, 2026 | Michael Celano | Chief Financial Officer | Acquired A | 37,604 | $0.00 | $0 | 215,785 | Direct |
| 26 Jan, 2026 | Gopi Shankar | Chief Development Officer | Acquired A | 25,637 | $0.00 | $0 | 76,443 | Direct |
| 26 Jan, 2026 | Russell Clayton | Chief Medical Officer | Acquired A | 25,637 | $0.00 | $0 | 71,443 | Direct |
| 26 Jan, 2026 | Michael Celano | Chief Financial Officer | Acquired A | 225,622 | $0.00 | $0 | 225,622 | Direct |
| 26 Jan, 2026 | Gopi Shankar | Chief Development Officer | Acquired A | 153,822 | $0.00 | $0 | 153,822 | Direct |